Extracellular matrix macromolecules present cancer cells with a structural barrier that serves to limit their unregulated growth and movement (1, 2). In turn, cancer cells have been postulated to use matrix metalloproteinases (MMPs), 2 a class of zinc-dependent proteolytic enzymes, as a means to dissolve these extracellular matrix barriers during neoplastic progression (1-3). Although the human MMP family is comprised of 16 secreted and seven membrane-tethered enzymes, increasing evidence suggests that a subclass of the membrane-anchored proteinases, termed the membrane type (MT) MMPs, plays dominant roles in controlling cancer cell behavior (1, 4 -8). The MT-MMPs are expressed either as type I transmembrane proteins (i.e. MT1, 2, 3, and 5 MMPs) or in a glycosylphosphatidylinositol-anchored format (i.e. MT4-and MT6-MMP) (1). Among these enzymes, MT1-MMP is considered to be the family member most closely linked to neoplastic cell behavior (6,8).Indeed, recent studies have demonstrated that MT1-MMP plays a direct and essential role in allowing tumor cells to degrade and invade multiple connective tissue barriers through a mechanism independent of MMP-2, an effector protease that operates downstream of MT1-MMP (4, 7).Synthesized as a catalytically inactive proenzyme, the MT1-MMP precursor undergoes proteolytic processing in the transGolgi complex wherein the prodomain is removed by members of the proprotein convertase family (9). Subsequently, the mature enzyme traffics to the plasma membrane via a process controlled by Rab8 and the microtubular apparatus (6, 10). Little is known with regard to the signaling molecules that mobilize MT1-MMP to the cell surface, but EGF, an extracellular ligand of EGF receptor family members (EGFRs; also known as ERBB/HERs), has been reported to induce cancer invasion by modulating MT1-MMP expression (11,12). Once delivered to the cell surface, the short cytoplasmic tail of MT1-MMP regulates its internalization and turnover at the plasma membrane, possibly through its interactions with adaptor protein 2, which resides in clathrin-coated pits (13,14). Migrating cells are then thought to localize MT1-MMP to various cellular domains by * This work was supported, in whole or in part, by National Institutes of Health Grants CA71699 (to S. J. W.) and HL77448 (Y.-J. S.). This work was also supported by grants from Wallace H. Coulter Foundation and the Beckman Laser Institute, Inc. (to Y. W.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. ⥠S The on-line version of this article (available at http://www.jbc.org) contains supplemental text, Movies S1-S5,